Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
Reviewers viewed the targeting of TFAM as innovative and the study's conclusions as potentially important (especially the effects on inflammation). However, the lack of evidence for a direct effect of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback